Windtree Therapeutics has signed a $520 million new financing agreement, which will be used to purchase BNB.

BlockBeats News, July 25th, Nasdaq-listed biotechnology company Windtree Therapeutics (WINT) announced that it has entered into a share purchase agreement of up to $500 million to establish an Equity Line of Credit (ELOC). Additionally, the company has also signed an additional $20 million stock purchase agreement with Build and Build Corp.

The total funding size of this round reaches up to $520 million, with 99% of the funds to be used to purchase BNB. The company plans to officially start using the funds after obtaining shareholder approval to increase the number of authorized common shares.